Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4476
CALL
Schrodinger
SDGR
$1.4B
| $111K | ﹤0.01% |
6,200
| – | – |
|
|
DFDV
4477
DeFi Development Corp
DFDV
$85.8M
| $111K | ﹤0.01% |
21,911
+14,422
| +193% | +$132K |
|
4478
Seres Therapeutics
MCRB
$46.6M
| $111K | ﹤0.01% |
7,432
+6,024
| +428% | +$105K |
|
4479
Freedom Holding
FRHC
$9.63B
| $110K | ﹤0.01% |
904
+775
| +601% | +$112K |
|
4480
PrimeEnergy Resources
PNRG
$315M
| $109K | ﹤0.01% |
637
+161
| +34% | +$25.9K |
|
4481
Sera Prognostics
SERA
$77.9M
| $108K | ﹤0.01% |
36,722
+26,726
| +267% | +$86.2K |
|
|
CANG
4482
Cango Inc
CANG
$70.6M
| $108K | ﹤0.01% |
7,212
+3,606
| +100% | +$98.8K |
|
4483
Innovator US Equity Ultra Buffer ETF June
UJUN
$188M
| $108K | ﹤0.01% |
2,888
-25
| -0.9% | -$924 |
|
4484
TransAlta
TAC
$3.95B
| $108K | ﹤0.01% |
8,519
-264,266
| -97% | -$3.95M |
|
4485
FT Vest US Equity Moderate Buffer ETF February
GFEB
$380M
| $107K | ﹤0.01% |
2,574
-2,384
| -48% | -$97.6K |
|
|
SI
4486
Shoulder Innovations Inc
SI
$409M
| $107K | ﹤0.01% |
7,457
+722
| +11% | +$9.84K |
|
4487
Direxion Daily FTSE China Bull 3X ETF
YINN
$697M
| $106K | ﹤0.01% |
2,500
-4,869
| -66% | -$231K |
|
4488
Gaia
GAIA
$31.5M
| $106K | ﹤0.01% |
29,198
+1,406
| +5% | +$6.43K |
|
4489
PUT
Illumina
ILMN
$29.1B
| $105K | ﹤0.01% |
800
| – | – |
|
4490
Karooooo
KARO
$1.93B
| $104K | ﹤0.01% |
2,296
-3,670
| -62% | -$172K |
|
4491
Atomera
ATOM
$217M
| $104K | ﹤0.01% |
47,051
+5,220
| +12% | +$15.8K |
|
|
HVII
4492
Hennessy Capital Investment Corp VII
HVII
$274M
| $104K | ﹤0.01% |
+10,000
| New | +$104K |
|
4493
Universal Electronics
UEIC
$74.6M
| $103K | ﹤0.01% |
28,608
| – | – |
|
|
QIPT
4494
DELISTED
Quipt Home Medical
QIPT
| $103K | ﹤0.01% |
29,166
| – | – |
|
|
OBE
4495
Obsidian Energy
OBE
$710M
| $102K | ﹤0.01% |
16,700
-726
| -4% | -$4.39K |
|
|
LFT
4496
Lument Finance Trust
LFT
$36.8M
| $102K | ﹤0.01% |
72,344
+7,594
| +12% | +$12.1K |
|
|
LGCY
4497
Legacy Education Inc
LGCY
$135M
| $102K | ﹤0.01% |
9,965
+8,189
| +461% | +$78.8K |
|
4498
Vanguard Real Estate ETF
VNQ
$38.3B
| $101K | ﹤0.01% |
1,143
-2,467
| -68% | -$222K |
|
4499
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$287M
| $101K | ﹤0.01% |
2,806
-251
| -8% | -$12.6K |
|
4500
PUT
Quantum Computing Inc
QUBT
$2.03B
| $101K | ﹤0.01% |
+9,800
| New | +$139K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.